Z. Chen

1.6k total citations · 2 hit papers
21 papers, 759 citations indexed

About

Z. Chen is a scholar working on Dermatology, Physiology and Immunology and Allergy. According to data from OpenAlex, Z. Chen has authored 21 papers receiving a total of 759 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Dermatology, 11 papers in Physiology and 7 papers in Immunology and Allergy. Recurrent topics in Z. Chen's work include Dermatology and Skin Diseases (16 papers), Asthma and respiratory diseases (11 papers) and Urticaria and Related Conditions (6 papers). Z. Chen is often cited by papers focused on Dermatology and Skin Diseases (16 papers), Asthma and respiratory diseases (11 papers) and Urticaria and Related Conditions (6 papers). Z. Chen collaborates with scholars based in United States, Germany and United Kingdom. Z. Chen's co-authors include Gianluca Pirozzi, Neil M.H. Graham, Bolanle Akinlade, Laurent Eckert, A. Gadkari, Allen Radin, Thomas Hultsch, Brad Shumel, Diamant Thaçi and Marius Ardeleanu and has published in prestigious journals such as Annals of Oncology, Journal of Investigative Dermatology and British Journal of Dermatology.

In The Last Decade

Z. Chen

16 papers receiving 750 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

2017 344 citations Marjolein de Bruin‐Weller, Diamant Thaçi et al. British Journal of Dermatology profile →
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

2019 231 citations Gil Yosipovitch, Matthew Reaney et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Z. Chen United States	6	693	560	332	154	66	21	759
Ashley M. Yu Canada	8	301 0.4×	234 0.4×	170 0.5×	48 0.3×	65 1.0×	16	413
William Romero United States	9	321 0.5×	201 0.4×	94 0.3×	79 0.5×	62 0.9×	24	378
Jordan Rosen United States	10	353 0.5×	149 0.3×	97 0.3×	147 1.0×	63 1.0×	25	479
Evangeline Pierce United States	12	374 0.5×	258 0.5×	96 0.3×	83 0.5×	48 0.7×	69	447
Anna Ascott United Kingdom	7	253 0.4×	173 0.3×	103 0.3×	42 0.3×	49 0.7×	14	312
Claudia Riepe Germany	8	252 0.4×	108 0.2×	79 0.2×	102 0.7×	33 0.5×	12	299
Luna Sun United States	9	195 0.3×	148 0.3×	76 0.2×	64 0.4×	47 0.7×	25	253
Lauren Becker United States	6	291 0.4×	201 0.4×	166 0.5×	52 0.3×	87 1.3×	7	377
Raveena Khanna United States	13	313 0.5×	94 0.2×	75 0.2×	114 0.7×	48 0.7×	31	392
Hajime Katsumata Japan	6	144 0.2×	178 0.3×	214 0.6×	21 0.1×	73 1.1×	7	339

Countries citing papers authored by Z. Chen

Since Specialization

Citations

This map shows the geographic impact of Z. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Z. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Z. Chen more than expected).

Fields of papers citing papers by Z. Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Z. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Z. Chen. The network helps show where Z. Chen may publish in the future.

Co-authorship network of co-authors of Z. Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Z. Chen. A scholar is included among the top collaborators of Z. Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Z. Chen. Z. Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Z., et al.. (2025). Dissolving cinnamaldehyde HA/PVA microneedles for the treatment of skin diseases caused by Microsporum canis. Journal of Drug Delivery Science and Technology. 107. 106841–106841.

Lü, Hongguang, et al.. (2025). Risk factors for anxiety and depression in patients with atopic dermatitis and their impact on prognosis. World Journal of Psychiatry. 15(6). 104738–104738.

Pavord, Ian, E. Israel, S.J. Szefler, et al.. (2023). Dupilumab Induces Clinical Remission in Patients With Uncontrolled, Moderate-to-Severe, Type 2 Inflammatory Asthma. A5995–A5995. 6 indexed citations

Migden, Michael R., Danny Rischin, Stacie Hudgens, et al.. (2020). 1087P Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial. Annals of Oncology. 31. S738–S738. 1 indexed citations

Simpson, Eric L., Lisa A. Beck, Mark Boguniewicz, et al.. (2020). 384 Dupilumab provides early and sustained, clinically-meaningful improvements in both adults and adolescents: A post hoc analysis of patients not achieving Investigator’s Global Assessment of 0/1 in phase 3 trials, LIBERTY AD SOLO 1 and 2, and LIBERTY AD ADOL. Journal of Investigative Dermatology. 140(7). S49–S49. 1 indexed citations

Merola, Joseph F., Robert Sidbury, Andreas Wollenberg, et al.. (2020). 409 Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week, randomized, controlled, phase 3 trial. Journal of Investigative Dermatology. 140(7). S53–S53. 1 indexed citations

Armstrong, April W., Andrew Blauvelt, Eric L. Simpson, et al.. (2020). 382 Dupilumab treatment provides continued improvements in signs and symptoms through week 100 in patients with moderate-to-severe atopic dermatitis who did not achieve ≥75% reduction in eczema area and severity index at week 16. Journal of Investigative Dermatology. 140(7). S49–S49. 1 indexed citations

Wollenberg, Andreas, Lisa A. Beck, Andrew Blauvelt, et al.. (2019). Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). British Journal of Dermatology. 182(5). 1120–1135. 91 indexed citations

Silverberg, Jonathan I., Eric L. Simpson, Marius Ardeleanu, et al.. (2019). Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. British Journal of Dermatology. 181(1). 80–87. 44 indexed citations

10.

Hamilton, Jennifer D., Z. Chen, Eric L. Simpson, et al.. (2019). 162 Biomarkers CCL17/TARC and Total IgE Do Not Predict Clinical Response to Dupilumab in Atopic Dermatitis (AD): a Post hoc Analysis of Pooled Phase 3 Data (SOLO 1 & 2). Journal of Investigative Dermatology. 139(9). S241–S241. 1 indexed citations

11.

Silverberg, Jonathan I., Emma Guttman‐Yassky, A. Gadkari, et al.. (2019). 673 Real-world persistence with dupilumab among adults with atopic dermatitis (AD). Journal of Investigative Dermatology. 139(5). S116–S116. 1 indexed citations

12.

Eichenfield, Lawrence F., A. Gadkari, April W. Armstrong, et al.. (2019). 692 Real-world effectiveness of dupilumab based on Investigator Global Assessment (IGA) and peak Pruritus Numerical Rating Scale (PNRS) scores. Journal of Investigative Dermatology. 139(5). S119–S119. 1 indexed citations

13.

Rischin, Danny, Nikhil I. Khushalani, Chrysalyne D. Schmults, et al.. (2019). Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC). Annals of Oncology. 30. xi35–xi36.

14.

Yosipovitch, Gil, Matthew Reaney, Vera Mastey, et al.. (2019). Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis. British Journal of Dermatology. 181(4). 761–769. 231 indexed citations breakdown →

15.

Katoh, Norito, Yoko Kataoka, Hidehisa Saeki, et al.. (2019). Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials. British Journal of Dermatology. 183(1). 39–51. 30 indexed citations

16.

Bruin‐Weller, Marjolein de, A. Gadkari, S. Auziere, et al.. (2019). 714 Productivity losses in adults with atopic dermatitis (AD): A cross-sectional study from clinical practices in Europe and Canada. Journal of Investigative Dermatology. 139(5). S122–S122.

17.

Simpson, Eric L., Thomas Bieber, Marjolein de Bruin‐Weller, et al.. (2018). 489 Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (liberty ad solo 1&2, chromos, cafe). Journal of Investigative Dermatology. 138(5). S83–S83. 1 indexed citations

18.

Hamilton, Jennifer D., Z. Chen, Lisa A. Beck, et al.. (2018). 1066 Biomarkers CCL17/TARC and total IgE do not predict clinical response to dupilumab in atopic dermatitis (AD): A post hoc analysis of pooled phase 3 data (SOLO 1 & 2). Journal of Investigative Dermatology. 138(5). S181–S181. 3 indexed citations

19.

Wei, Wenhui, Michael Andria, Valery Walker, et al.. (2017). 204 A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): Baseline treatment patterns and unmet needs assessment. Journal of Investigative Dermatology. 137(5). S35–S35. 1 indexed citations

20.

Thaçi, Diamant, Andreas Wollenberg, Anita Remitz, et al.. (2017). Le dupilumab lors de dermatite atopique modérée à sévère : résultats groupés de deux études randomisées de phase III (SOLO 1 et 2). Annales de Dermatologie et de Vénéréologie. 144(12). S266–S267. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact